Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice
Jazyk angličtina Země Švýcarsko Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie
PubMed
30099450
DOI
10.1159/000492079
PII: 000492079
Knihovny.cz E-zdroje
- Klíčová slova
- Clinical practice, Depression, Individualized treatment, Multimodal antidepressant, Trazodone, Treatment-resistant depression,
- MeSH
- antidepresiva druhé generace aplikace a dávkování škodlivé účinky MeSH
- deprese farmakoterapie MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- nežádoucí účinky léčiv MeSH
- prospektivní studie MeSH
- psychiatrické posuzovací škály MeSH
- rozvrh dávkování léků MeSH
- selektivní inhibitory zpětného vychytávání serotoninu aplikace a dávkování škodlivé účinky MeSH
- senioři MeSH
- trazodon aplikace a dávkování škodlivé účinky MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- Názvy látek
- antidepresiva druhé generace MeSH
- selektivní inhibitory zpětného vychytávání serotoninu MeSH
- trazodon MeSH
OBJECTIVE: The aim of the study was to evaluate the efficacy, tolerability, and safety of once-a day trazodone tablets (Trittico Prolong® 300 mg) in patients with moderate to severe depression in routine clinical practice. METHODS: Men and women ≥18 years old with Montgomery-Åsberg Depression Rating Scale (MADRS) scores > 21 and Clinical Global Impression - Severity (CGI/S) ≥4 were included in this post-authorization, non-interventional, observational prospective safety study, conducted in 8 psychiatric centers in the Czech -Republic. The acute treatment phase lasted 5 weeks: 1 week of titration and 4 weeks of full-dose treatment. Patients had follow-up visits 9 and 21 weeks after commencing -treatment. RESULTS: Overall, 85 patients were enrolled in the study, of which 80 completed the acute treatment of 5 weeks. There were significant decreases in the overall MADRS score from the baseline mean value of 27.4-21.2 at week 1 (p < 0.001), and a further decrease to 7.9 at week 5 (p < 0.001). The severity of depression according to CGI/S gradually declined. Most patients reported improvement after 6 days of trazodone treatment. The most frequent adverse drug reactions (ADRs) reported were somnolence and fatigue. CONCLUSIONS: Trazodone, in the new extended-release formulation, had very good effects in clinical practice, both in previously untreated depressive episodes and in episodes not responsive to previous antidepressive therapy.
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Medical Angelini Pharma Brno Czech Republic
Department of Psychiatry Faculty Hospital Brno Brno Czech Republic
Department of Psychiatry University Hospital Ostrava Ostrava Czech Republic
Department of Psychology Faculty of Arts Masaryk University Brno Czech Republic
Institute of Biostatistics and Analyses Brno Brno Czech Republic
Citace poskytuje Crossref.org
